Key terms
About INM
InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. It is also involved in cannabinoid-based therapies and a biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. It operates through the InMed and BayMedica segments. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest INM news
Today
8:49am ET
InMed’s INM-089 Shows Promise for AMD Treatment
Apr 05
11:42am ET
InMed Pharmaceuticals Excites with Alzheimer’s Breakthrough
Apr 04
8:37am ET
InMed’s INM-901 Shows Promise Against Alzheimer’s
Mar 20
1:52pm ET
InMed Pharmaceuticals Granted Nasdaq Compliance Extension
Mar 20
9:08am ET
InMed Pharmaceuticals Receives Nasdaq Extension
Feb 10
4:17am ET
InMed Pharmaceuticals Announces New CFO Appointment
Feb 10
4:17am ET
InMed Pharmaceuticals Welcomes New CFO Neeta Jagpal
No recent news articles are available for INM
Today
8:00am ET
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration
Apr 04
8:00am ET
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies
Mar 20
8:30am ET
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
INM Financials
Key terms
Ad Feedback
INM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
INM Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
